Dr. Matthew Martinez on the New AHA/ACC Hypertrophic Cardiomyopathy Guideline

The American Heart Association (AHA)/American College of Cardiology (ACC) Joint Committee on Clinical Practice Guidelines recently published a guideline for the evaluation and management of patients with hypertrophic cardiomyopathy (HCM). The new guideline recommends CAMZYOS (mavacamten), the first and only US Food and Drug Administration-approved cardiac myosin inhibitor, as a Class 1 Level B-R therapy for the treatment of adults with obstructive HCM (oHCM) who have persistent symptoms after first-line therapy (beta blockers or non-dihydropyridine calcium channel blockers).

DocWire News spoke with Matthew W. Martinez, MD, of Atlantic Health System, about the significance of the updated guideline in the treatment of symptomatic oHCM and how it equips cardiologists with evidence-based recommendations for prescribing CAMZYOS to patients who do not derive adequate symptomatic relief from first-line drug therapy.